Table 2 Response to The Treatment

From: Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial

 

Efficacy population (n = 23)

 

The end of 3 cycles of scheduled treatment

Completion of 6 cycles of scheduled treatment

Complete response

4

(17.4%)

13

(56.5%)

Partial response

17

(73.9%)

9

(39.1%)

Stable disease

2

(8.7%)

1

(4.3%)

Objective response rate

21

(91.3%; 72–98.9)

22

(95.7%; 78.1–99.9)

Complete response rate

4

(17.4%; 5.0–38.8)

13

(56.5%; 34.5–76.8)

Disease control rate

23

(100%; 100–100)

23

(100%; 100–100)

  1. Data are n (%), or n (%; 95% CI). Percentages (%) might not total 100% because of rounding. 95% CI = 95% confidence interval.
Back to article page